Redx to set up HQ at ex-AstraZeneca site in consolidation of R&D teams

Alderley Park

Redx Pharma (LON:REDX) is set to open a new headquarters at AstraZeneca’s ($AZN) former Alderley Park site. The opening of the headquarters, which will double Redx’s footprint at Alderley Park, will enable the biotech to consolidate its disaggregated R&D teams, specifically by bringing the oncology group across from its current home in Liverpool.

Once the move is complete, something Redx expects to happen by the end of the year, the biotech will house all of its 193 employees in a 74,000-square-feet facility at Alderley Park. Currently, the 88 employees who make up Redx Oncology, one of the company’s three subsidiaries, are based out of a site at the Royal Liverpool University Hospital, around a 40-mile drive from Alderley Park. The team is being forced to move out of digs in Liverpool because the building it occupies is set to be demolished next year.

While the demolition is forcing Redx to move the oncology team, it also sees value in consolidating R&D staffers from across its three subsidiaries at one site. “Bringing our three teams together will support our ambitious growth plans and give the business some valuable human, scientific and logistical synergies,” Redx CEO Neil Murray said in a statement. “Alderley Park’s high-specification laboratories and superlative facilities present a commercially attractive solution as we seek to provide the best infrastructure and environment for our staff.”

Virtual Event

Virtual Clinical Trials Online

This virtual event will bring together industry experts to discuss the increasing pace of pharmaceutical innovation, the need to maintain data quality and integrity as new technologies are implemented and understand regulatory challenges to ensure compliance.

The move represents a boost for the team now running Alderley Park, too. Since picking up the site in a deal reported at the time to be worth upward of £30 million ($43 million), Manchester Science Parks has set about trying to turn the former Big Pharma campus into a multi-occupancy life science hub. The strategy is backed by a planned £30 million investment over the next couple of years, a sum the owners expect to result in the site having 1.5 million square feet of lettable laboratory and work space.

- read the statement

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.